These 4 anti-obesity drug stocks could soar, Berenberg says
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs,…